Keros Therapeutics, Inc. Stock-Based Compensation
Keros Therapeutics, Inc. (KROS) reported Stock-Based Compensation of $11.58 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-03
- Keros Therapeutics, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $5.38M, a 37.05% decline year-over-year.
- Keros Therapeutics, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $6.20M, a 30.06% decline year-over-year.
- Keros Therapeutics, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $7.30M, a 20.60% decline year-over-year.
- Keros Therapeutics, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $3.99M, a 54.79% decline year-over-year.
- Keros Therapeutics, Inc. share-based payment arrangement, noncash expense for fiscal 2025 was $28.70M, a 17.71% decline from fiscal 2024.
- Keros Therapeutics, Inc. share-based payment arrangement, noncash expense for fiscal 2024 was $34.87M, a 21.24% increase from fiscal 2023.
- Keros Therapeutics, Inc. share-based payment arrangement, noncash expense for fiscal 2023 was $28.76M, a 53.96% increase from fiscal 2022.
- Keros Therapeutics, Inc. share-based payment arrangement, noncash expense for fiscal 2022 was $18.68M, a 59.38% increase from fiscal 2021.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $5.38M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | $11.58M 10-Q · filed 2026-08-03 | $18.88M derived: sum of 3 quarters · filed 2026-08-03 | $22.87M derived: sum of 4 quarters · filed 2026-08-03 |
| 2026-03-31 | $6.20M 10-Q · filed 2026-05-14 | $13.50M derived: sum of 2 quarters · filed 2026-05-14 | $17.49M derived: sum of 3 quarters · filed 2026-05-14 | $26.03M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-12-31 | $7.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | $11.29M derived: sum of 2 quarters · filed 2026-03-04 | $19.83M derived: sum of 3 quarters · filed 2026-08-03 | $28.70M 10-K · filed 2026-03-04 |
| 2025-09-30 | $3.99M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $12.53M derived: sum of 2 quarters · filed 2026-08-03 | $21.39M 10-Q · filed 2025-11-05 | $30.59M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-06-30 | $8.54M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | $17.41M 10-Q · filed 2026-08-03 | $26.61M derived: sum of 3 quarters · filed 2026-08-03 | $35.42M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-03-31 | $8.86M 10-Q · filed 2026-05-14 | $18.06M derived: sum of 2 quarters · filed 2026-05-14 | $26.88M derived: sum of 3 quarters · filed 2026-05-14 | $35.66M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $9.20M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | $18.02M derived: sum of 2 quarters · filed 2026-03-04 | $26.80M derived: sum of 3 quarters · filed 2026-03-04 | $34.87M 10-K · filed 2026-03-04 |
| 2024-09-30 | $8.82M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $17.60M derived: sum of 2 quarters · filed 2025-11-05 | $25.67M 10-Q · filed 2025-11-05 | $33.00M derived: sum of 4 quarters · filed 2025-11-05 |
| 2024-06-30 | $8.79M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $16.86M 10-Q · filed 2025-08-06 | $24.18M derived: sum of 3 quarters · filed 2025-08-06 | $32.89M derived: sum of 4 quarters · filed 2025-08-06 |
| 2024-03-31 | $8.07M 10-Q · filed 2025-05-06 | $15.39M derived: sum of 2 quarters · filed 2025-05-06 | $24.11M derived: sum of 3 quarters · filed 2025-05-06 | $31.15M derived: sum of 4 quarters · filed 2025-05-06 |
| 2023-12-31 | $7.32M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $16.04M derived: sum of 2 quarters · filed 2025-02-26 | $23.08M derived: sum of 3 quarters · filed 2025-02-26 | $28.76M 10-K · filed 2025-02-26 |
| 2023-09-30 | $8.71M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $15.75M derived: sum of 2 quarters · filed 2024-11-06 | $21.44M 10-Q · filed 2024-11-06 | $26.18M derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-06-30 | $7.04M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $12.73M 10-Q · filed 2024-08-07 | $17.47M derived: sum of 3 quarters · filed 2025-02-26 | $22.23M derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-03-31 | $5.69M 10-Q · filed 2024-05-08 | $10.43M derived: sum of 2 quarters · filed 2025-02-26 | $15.19M derived: sum of 3 quarters · filed 2025-02-26 | $19.98M derived: sum of 4 quarters · filed 2025-02-26 |
| 2022-12-31 | $4.75M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $9.50M derived: sum of 2 quarters · filed 2025-02-26 | $14.29M derived: sum of 3 quarters · filed 2025-02-26 | $18.68M 10-K · filed 2025-02-26 |
| 2022-09-30 | $4.75M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | $9.55M derived: sum of 2 quarters · filed 2023-11-06 | $13.94M 10-Q · filed 2023-11-06 | $17.23M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | $4.79M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | $9.18M 10-Q · filed 2023-08-07 | $12.48M derived: sum of 3 quarters · filed 2024-02-28 | $15.56M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-03-31 | $4.39M 10-Q · filed 2023-05-04 | $7.68M derived: sum of 2 quarters · filed 2024-02-28 | $10.77M derived: sum of 3 quarters · filed 2024-02-28 | $13.62M derived: sum of 4 quarters · filed 2024-02-28 |
| 2021-12-31 | $3.29M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $6.38M derived: sum of 2 quarters · filed 2024-02-28 | $9.23M derived: sum of 3 quarters · filed 2024-02-28 | $11.72M 10-K · filed 2024-02-28 |
| 2021-09-30 | $3.08M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $5.93M derived: sum of 2 quarters · filed 2022-11-03 | $8.43M 10-Q · filed 2022-11-03 | $9.95M derived: sum of 4 quarters · filed 2022-11-03 |
| 2021-06-30 | $2.85M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $5.34M 10-Q · filed 2022-08-04 | $6.87M derived: sum of 3 quarters · filed 2022-08-04 | $8.29M derived: sum of 4 quarters · filed 2022-08-04 |
| 2021-03-31 | $2.49M 10-Q · filed 2022-05-05 | $4.02M derived: sum of 2 quarters · filed 2022-05-05 | $5.44M derived: sum of 3 quarters · filed 2022-05-05 | $6.58M derived: sum of 4 quarters · filed 2022-05-05 |
| 2020-12-31 | $1.52M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-09 | $2.95M derived: sum of 2 quarters · filed 2022-03-09 | $4.08M derived: sum of 3 quarters · filed 2022-03-09 | $4.10M 10-K · filed 2022-03-09 |
| 2020-09-30 | $1.42M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $2.56M derived: sum of 2 quarters · filed 2021-11-04 | $2.58M 10-Q · filed 2021-11-04 | $2.59M derived: sum of 4 quarters · filed 2021-11-04 |
| 2020-06-30 | $1.14M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $1.15M 10-Q · filed 2021-08-05 | $1.17M derived: sum of 3 quarters · filed 2021-08-05 | $1.19M derived: sum of 4 quarters · filed 2021-08-05 |
| 2020-03-31 | $12.00K 10-Q · filed 2021-05-06 | $30.00K derived: sum of 2 quarters · filed 2021-05-06 | $47.00K derived: sum of 3 quarters · filed 2021-05-06 | $60.00K derived: sum of 4 quarters · filed 2021-05-06 |
| 2019-12-31 | $18.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | $35.00K derived: sum of 2 quarters · filed 2021-03-25 | $48.00K derived: sum of 3 quarters · filed 2021-03-25 | $59.00K 10-K · filed 2021-03-25 |
| 2019-09-30 | $17.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-10 | $30.00K derived: sum of 2 quarters · filed 2020-11-10 | $41.00K 10-Q · filed 2020-11-10 | |
| 2019-06-30 | $13.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-13 | $24.00K 10-Q · filed 2020-08-13 | ||
| 2019-03-31 | $11.00K 10-Q · filed 2020-05-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |